Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)

被引：0
|
作者：
Van Herpen, C.
Fiedler, W.
Toma, S.
Marreaud, S.
Van Laarhoven, H.
Lasch, P.
Bogaerts, J.
Heerschap, A.
Bordignon, C.
Punt, C.
机构：
[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[2] Univ Hosp Hamburg Eppendorf, Dept Med 2, Hamburg, Germany
[3] Molmed, Milan, Italy
[4] EORTC, Brussels, Belgium
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiol, Nijmegen, Netherlands
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70371-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [21] Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours
    B C Goh
    E E Vokes
    A Joshi
    M J Ratain
    British Journal of Cancer, 2002, 86 : 534 - 539
  • [22] A phase I safety and IRK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression
    Jonker, DJ
    Avruch, L
    Stewart, DJ
    Goel, R
    Goss, G
    Dent, S
    Reaume, MN
    Spencer, TA
    Peters, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 214S - 214S
  • [23] NGR-TNF, a novel direct-acting vascular targeting agent, does not induce "cytokine-rebound" recruitment of pro-angiogenic bone-marrow derived cells
    Di Matteo, Paola
    Hack, Christina
    Jedeszko, Christopher
    Valentinis, Barbara
    Bordignon, Claudio
    Traversari, Catia
    Kerbel, Robert S.
    Rizzardi, Gian-Paolo
    CANCER RESEARCH, 2011, 71
  • [24] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Rimassa, L.
    Bennicelli, E.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] PHASE II STUDY OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), ADMINISTERED AS SINGLE AGENT AT LOW DOSE IN PATIENTS (PTS) WITH COLORECTAL CANCER (CRC) REFRACTORY TO STANDARD REGIMENS
    Rimassa, L.
    Sobrero, A.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [26] Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M. LoRusso
    Shirish M. Gadgeel
    Antoinette Wozniak
    Alan J. Barge
    Helen K. Jones
    Zachary S. DelProposto
    Pamela A. DeLuca
    Jeffrey L. Evelhoch
    Scott A. Boerner
    Catherine Wheeler
    Investigational New Drugs, 2008, 26 : 159 - 167
  • [27] Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    LoRusso, Patricia M.
    Gadgeel, Shirish M.
    Wozniak, Antoinette
    Barge, Alan J.
    Jones, Helen K.
    DelProposto, Zachary S.
    DeLuca, Pamela A.
    Evelhoch, Jeffrey L.
    Boerner, Scott A.
    Wheeler, Catherine
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) : 159 - 167
  • [28] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Rimassa, L.
    Sobrero, A. F.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
    Patterson, D. M.
    Ross, P.
    Koetz, B.
    Saleem, A.
    Stratford, M.
    Stirling, J.
    Padhani, A.
    Asselin, M.
    Price, P.
    Rustin, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS
    Zucali, P. A.
    Santoro, A.
    Simonelli, M.
    De Vincenzo, F.
    Lorenzi, E.
    Rimassa, L.
    Balzarini, L.
    Quagliuolo, V.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 173 - 173
12345